PSP Research’s Cytokinetics CYTK Stock Holding History

PSP Research’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-8,300	Closed	-$547K	–	80
2026 Q1	$547K	Sell	8,300 -13	-0.2%	-$826	0.39%	8
2025 Q4	$528K	Buy	+8,313	New	+$517K	0.46%	47

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PSP Research's CYTK Position: Q2 2026 in Review

PSP Research sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 8,300 shares — an estimated $547K sold.

PSP Research first reported a position in CYTK in Q4 2025 and held it in 2 quarters. The position peaked at $547K in Q1 2026. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

PSP Research reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
PSP Research sold 8,300 Cytokinetics shares in Q2 2026, an estimated $547K.
PSP Research first reported a position in Cytokinetics in Q4 2025 and held it in 2 quarters.
PSP Research's Cytokinetics position peaked at $547K in Q1 2026.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.